News Release

New study suggests N95 respirators can be safely reprocessed to augment supply in future epidemics

Findings published in the American Journal of Infection Control suggest no significant differences in respirator function or effectiveness after 25 decontamination cycles

Peer-Reviewed Publication

Association for Professionals in Infection Control

Arlington, Va., January 6, 2022 – Results from a study published today in the American Journal of Infection Control (AJIC), suggest that a common type of N95 respirator can be safely reprocessed to augment supply during future epidemics. Researchers at Beth Israel Deaconess Medical Center and Massachusetts institute of Technology (MIT) reprocessed respirators using vaporized hydrogen peroxide (VHP), a standard decontamination approach, and found that the devices maintained their function and effectiveness on human subjects with up to 25 cycles of re-use.

N95 respirators are commonly used in hospitals worldwide to protect healthcare personnel from infectious pathogens. During the SARS-CoV-2 pandemic, healthcare facilities experienced shortages of the respirators, forcing personnel to re-use them or resort to less protective alternatives (e.g., facial masks).

“The findings from our study expand upon previous findings that VHP is a relatively safe method for reprocessing N95 respirators, and could help address shortages in future epidemics,” said Christina F. Yen, MD, infectious diseases physician who completed her healthcare epidemiology and infection control training at Beth Israel Deaconess Medical Center and the paper’s lead author. “It is important that we now find ways to scale and translate this capability to smaller hospitals and resource-limited healthcare settings that could benefit just as much – perhaps more – from this type of personal protective equipment reprocessing in future disaster scenarios.”

Dr. Yen and colleagues used VHP to serially decontaminate seven N95 respirators. After each VHP cycle, they conducted a series of qualitative and quantitative tests to evaluate both the function and effectiveness of the respirators on human subjects as compared to baseline. These tests comprised a user seal check (performed by subjects donning and doffing the respirators), qualitative and quantitative respirator fit testing, and filtration efficiency testing, which assesses the ability of the respirator to filter out particles.

Results published today in AJIC, the journal of the Association for Professionals in Infection Control and Epidemiology (APIC), show that even after 25 decontamination cycles there were no alterations to respiratory integrity or filtration efficiency among the seven N95 respirators the researchers evaluated. All met the primary endpoints of function and effectiveness, passing 25 user seal checks and eight quantitative and four qualitative fit tests, in addition to maintaining filtration efficiencies of 95% or above throughout the study. As compared to baseline filtration efficiencies of 99% for particles between 0.3-10 µm in diameter, filtration rates after VHP reprocessing cycles 20 and 25 for 0.3-10 diameter particles were 99.9% and 99.6%, respectively. These changes were not statistically significant (p=0.10 after cycle 20 and p=0.05 after cycle 25).

The researchers noted that successful, large-scale implementation of N95 respirator reprocessing requires planning and coordination, multidisciplinary teams to ensure disinfection efficacy and end-user safety, and significant logistical support.

“In order for reprocessing to be a realistic option for healthcare facilities, certain steps need to be taken,” Yen said. Examples of these steps include creating relationships between infection prevention, occupational health, environmental services, and other relevant functions within hospitals to facilitate implementation of appropriate technologies and advocating for the inclusion of personal protective equipment reprocessing in epidemic and pandemic planning.

“The findings from this study are encouraging and valuable, particularly given the N95 respirator shortage we experienced during the COVID-19 pandemic,” said Ann Marie Pettis, BSN, RN, CIC, FAPIC, and APIC 2021 president. “The results make clear that investing in VHP capabilities now could help to ensure equitable access to personal protective equipment during any future pandemic.”

About APIC

Founded in 1972, the Association for Professionals in Infection Control and Epidemiology (APIC) is the leading association for infection preventionists and epidemiologists. With more than 15,000 members, APIC advances the science and practice of infection prevention and control. APIC carries out its mission through research, advocacy, and patient safety; education, credentialing, and certification; and fostering development of the infection prevention and control workforce of the future. Together with our members and partners, we are working toward a safer world through the prevention of infection. Join us and learn more at apic.org.

About AJIC

As the official peer-reviewed journal of APIC, The American Journal of Infection Control (AJIC) is the foremost resource on infection control, epidemiology, infectious diseases, quality management, occupational health, and disease prevention. Published by Elsevier, AJIC also publishes infection control guidelines from APIC and the CDC. AJIC is included in Index Medicus and CINAHL. Visit AJIC at ajicjournal.org.

NOTES FOR EDITORS

“Assessing changes to N95 respirator filtration efficiency, qualitative and quantitative fit, and seal check with repeated vaporized hydrogen peroxide (VHP) decontamination,” by Christina F. Yen, Robert Seeley, Patrick Gordon, Lalitha Parameswaran, Sharon B. Wright, Dana Pepe, and Preeti Mehrotra, was published online in AJIC on January 6, 2022. The article may be found online at:  https://doi.org/10.1016/j.ajic.2021.11.005.

 

AUTHORS

Christina F. Yen, MD (Corresponding author: christfyen@gmail.com)

Division of Infection Control/Hospital Epidemiology, Silverman Institute of Health Care

Quality & Safety, and Division of Infectious Diseases

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

Robert Seeley, MS, CSP

Department of Environmental Health and Safety

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

Patrick Gordon, DNP, RN, CIC

Division of Infection Control/Hospital Epidemiology, Silverman Institute of Health Care

Quality & Safety

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

Lalitha Parameswaran, Ph.D.

Massachusetts Institute of Technology, Lincoln Laboratory

Lexington, Massachusetts, USA

 

Sharon B. Wright, MD, MPH

Division of Infection Control/Hospital Epidemiology, Silverman Institute of Health Care

Quality & Safety, and Division of Infectious Diseases

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

Dana Pepe, MD, MPH

Division of Infection Control/Hospital Epidemiology, Silverman Institute of Health Care

Quality & Safety, and Division of Infectious Diseases

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

Preeti Mehrotra, MD, MPH

Division of Infection Control/Hospital Epidemiology, Silverman Institute of Health Care

Quality & Safety, and Division of Infectious Diseases

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

 

# # #


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.